Protara Therapeutics, Inc.
TARAFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Protara Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Protara Therapeutics, Inc. — 10-K filed Mar 20, 2015
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 13 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 16, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Protara Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-01 · Zummo Jacqueline: Larger than all 13 other insider sales of Common Stock on file. SEC filing
- 2025-03-26 · Zummo Jacqueline: Larger than 12 of the 13 other insider sales of Common Stock on file. SEC filing
- 2024-09-12 · Opaleye Management Inc.: Larger than 34 of the 35 other insider sales of Common Stock, par value $0.001 per share on file. SEC filing
- 2024-09-09 · Opaleye Management Inc.: Larger than 32 of the 35 other insider sales of Common Stock, par value $0.001 per share on file. SEC filing
- 2024-05-17 · Opaleye Management Inc.: Larger than 33 of the 35 other insider sales of Common Stock, par value $0.001 per share on file. SEC filing
- 2024-05-10 · Opaleye Management Inc.: Larger than all 35 other insider sales of Common Stock, par value $0.001 per share on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-04-08 | Zummo Jacqueline · Chief R&D Officer | Common Stock | S — Open market or private sale | −1,134 | 5.40 | SEC filing |
| 2026-04-01 | Zummo Jacqueline · Chief R&D Officer | Common Stock | S — Open market or private sale | −22,598 | 5.26 | SEC filing |
| 2025-05-14 (amended) | Levy Richard S · Director | Common Stock | P — Open market or private purchase | +20,000 | 3.19 | SEC filing |
| 2025-03-26 | Zummo Jacqueline · Chf Scientific Operations Off | Common Stock | S — Open market or private sale | −21,224 | 4.53 | SEC filing |
| 2024-09-12 | Opaleye Management Inc. · 10% owner | Common Stock, par value $0.001 per share | S — Open market or private sale | −6,500 | 1.71 | SEC filing |
| 2024-09-12 | Opaleye Management Inc. · 10% owner | Common Stock, par value $0.001 per share | S — Open market or private sale | −119,801 | 1.71 | SEC filing |
| 2024-09-11 | Opaleye Management Inc. · 10% owner | Common Stock, par value $0.001 per share | S — Open market or private sale | −31,000 | 1.71 | SEC filing |
| 2024-09-11 | Opaleye Management Inc. · 10% owner | Common Stock, par value $0.001 per share | S — Open market or private sale | −1,600 | 1.71 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-15 | GARCEAU ROGER · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-15 | BESHAR LUKE M · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-15 | SARGEN GREGORY · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-15 | Flannelly Barry P · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-15 | Smith Cynthia · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-15 | Huang Jane · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-15 | Levy Richard S · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-15 | Solomon Michael Edward · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.